BioSpace News Archive

Achieve Life Sciences, Inc., a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, announced publication of the ORCA-V1 trial results in the Journal of the American Medical Association Internal Medicine.

According to a new report by nova one advisor, the U.S. consumer genomics market size was valued at USD 485.90 million in 2023 and is anticipated to reach around USD 4,489.22 million by 2033, growing at a CAGR of 8.52% from 2024 to 2033.

Oxurion NV announces important progress in its preclinical program targeting Geographic Atrophy, a severe and underserved form of Age-Related Macular Degeneration.

CytoHub, Inc., a pioneering developer of intelligent technologies for cell therapy and regenerative medicine, announced the strategic addition of three top industry experts to its team.

The global scaffold technology market size was US$ 1,212.2 million in 2023 and is projected to surpass the market size of US$ 4,714.7 million by 2032, growing at a CAGR of 16.29% during the forecast period from 2024 to 2032.

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported the appointment of Darin Zehr to its Board of Directors, effective as of May 1, 2024.

Researchers at Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania revealed a powerful new bone marrow atlas that will offer the public a first-of-its-kind visual passport into the spectrum of healthy and diseased blood production.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended March 31, 2024.

Regeneron Pharmaceuticals, Inc. will webcast management participation as follows.

Assertio Holdings, Inc., a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, reported financial results for the first quarter ended March 31, 2024.